Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lorazepam
Drug ID BADD_D01318
Description Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic.[A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.[L5095]
Indications and Usage Lorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.[T385] Some off-label indications of lorazepam include rapid tranquilization of an agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, muscle spasms, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting, and psychogenic catatonia.[T385]
Marketing Status approved
ATC Code N05BA06
DrugBank ID DB00186
KEGG ID D00365
MeSH ID D008140
PubChem ID 3958
TTD Drug ID D0E0OG
NDC Product Code 0641-6047; 0641-6049; 0904-6008; 71554-009; 72166-001; 0093-3426; 0121-0770; 52427-663; 55154-7976; 60687-638; 65162-018; 68788-7533; 69315-904; 70518-0275; 70518-0445; 0641-6002; 0641-6048; 72789-236; 76329-8261; 0904-6007; 51927-0195; 67763-101; 76420-296; 0093-3427; 52427-661; 61919-062; 63187-536; 67296-1478; 67296-1622; 68071-5022; 0409-6778; 71205-235; 71335-1467; 71610-600; 72572-380; 0641-6000; 0641-6001; 0641-6003; 0641-6051; 48087-0076; 51927-1005; 55154-7975; 61919-607; 67296-1332; 67544-142; 71610-008; 71610-654; 71610-655; 58118-1095; 63304-773; 65162-687; 68071-4916; 68071-5250; 70518-0486; 70518-2186; 70518-2442; 71205-228; 71335-0329; 71335-1455; 71335-1694; 0641-6207; 57218-950; 0187-0064; 53002-5291; 58118-0904; 60760-516; 63187-576; 68071-2666; 70934-782; 72789-197; 72789-226; 0904-6009; 13107-085; 0187-0065; 50383-705; 54348-049; 60687-627; 60687-649; 63304-774; 65162-015; 71335-1138; 71610-255; 12828-0025; 0093-3425; 53002-6290; 67544-191; 68071-3096; 0409-1985; 68788-7355; 70518-1275; 70518-3188; 70518-3423; 71205-166; 71205-756; 71610-122; 71610-229; 71610-674; 0641-6044; 0641-6046; 0641-6050; 64330-020; 43353-255; 52427-658; 55154-7977; 63304-772; 68788-7428; 69315-906; 70518-2268; 70518-3225; 72189-351; 17478-040; 52427-667; 55700-778; 65162-017; 67544-261; 70518-1520; 0054-3532; 71335-0655; 49452-4140; 51552-0729; 13107-083; 50090-5508; 63629-2953; 68071-2662; 68071-3121; 68071-5068; 69315-905; 71610-178; 71610-199; 71610-225; 0641-6045; 52696-0002; 62991-1682; 13107-084; 45865-499; 0187-0063; 50090-5509; 58118-1096
UNII O26FZP769L
Synonyms Lorazepam | Ativan | Orfidal Wyeth | Wyeth, Orfidal | Témesta | Tolid | Donix | Duralozam | Durazolam | Idalprem | Laubeel | Lorazep Von Ct | Von Ct, Lorazep | Lorazepam Medical | Medical, Lorazepam | Lorazepam-Neuraxpharm | Lorazepam Neuraxpharm | Lorazepam-Ratiopharm | Lorazepam Ratiopharm | Novo-Lorazem | Novo Lorazem | Nu-Loraz | Nu Loraz | Sedicepan | Sinestron | WY-4036 | WY 4036 | WY4036 | Apo-Lorazepam | Apo Lorazepam | Somagerol | Temesta
Chemical Information
Molecular Formula C15H10Cl2N2O2
CAS Registry Number 846-49-1
SMILES C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tachyphrenia17.03.03.007; 19.10.03.010--Not Available
Age-related macular degeneration06.09.03.018--Not Available
Stress cardiomyopathy02.04.01.012; 24.04.04.0260.000154%Not Available
Respiratory fatigue22.02.01.0420.000092%Not Available
Hyporesponsive to stimuli17.02.05.0570.000160%Not Available
Poor feeding infant18.04.06.006; 14.03.02.0220.000031%Not Available
End stage renal disease20.01.03.0190.000031%Not Available
Tongue discomfort07.14.02.019--Not Available
Anisocoria17.02.11.009; 06.05.03.0130.000031%Not Available
Behaviour disorder19.01.01.0050.000031%Not Available
Drug ineffective for unapproved indication12.09.02.002; 08.06.01.0380.000413%Not Available
Drug use disorder19.07.06.0120.000108%Not Available
Illness08.01.03.091--Not Available
Implant site swelling12.07.02.063; 08.02.02.0630.000031%Not Available
Pharyngeal swelling22.04.05.028--Not Available
Pneumonitis aspiration22.01.01.0310.000077%Not Available
Post-injection delirium sedation syndrome19.13.02.004; 12.02.05.057; 17.02.04.0240.000031%Not Available
Sexually inappropriate behaviour19.05.01.0260.000031%Not Available
Suspected suicide19.12.01.009; 08.04.01.0170.000031%Not Available
Suspected suicide attempt19.12.01.0100.000031%Not Available
Therapeutic product effect decreased08.06.01.050--Not Available
Therapeutic product effect delayed08.06.01.051--Not Available
Therapeutic product effect incomplete08.06.01.052--Not Available
Therapeutic product effect variable08.06.01.0550.000031%Not Available
Therapeutic product ineffective08.06.01.057--Not Available
Therapy non-responder08.06.01.0630.000366%Not Available
Therapy partial responder08.06.01.0640.000108%Not Available
Withdrawal catatonia19.11.01.004; 08.06.02.0280.000031%Not Available
Brain fog19.21.02.017; 17.02.05.077; 16.32.03.050--Not Available
Exertional headache17.14.01.021--Not Available
The 16th Page    First    Pre   16 17    Next   Last    Total 17 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene